Milestone Pharmaceuticals Reports Financial Results
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) recently shared its financial results for the third quarter of 2025. The company is poised for significant developments as it approaches its PDUFA target date for CARDAMYST™ (etripamil) nasal spray.
Optimism Surrounding CARDAMYST Launch
With the Prescription Drug User Fee Act (PDUFA) target date set for December 13, 2025, there is a palpable sense of excitement around the potential approval of CARDAMYST for paroxysmal supraventricular tachycardia (PSVT). Joseph Oliveto, President and CEO of Milestone Pharmaceuticals, expressed optimism regarding the upcoming launch, emphasizing the importance of rapid market readiness.
Equity Financing Strengthens Financial Position
On September 30, 2025, the company reported a solid cash position of $82.6 million, bolstered by a successful equity offering earlier this year. The infusion of funds is expected to facilitate a swift and efficient launch of CARDAMYST following FDA approval.
Third Quarter Performance Highlights
Milestone continues to prepare extensively for the launch of its flagship product, CARDAMYST. The company's latest financial reporting reveals several key performance indicators for Q3 2025:
- As of September 30, 2025, Milestone recorded no revenue for the third quarter or the same period the previous year.
- Research and development expenses reached $3.9 million, slightly lower than the $4 million reported in the previous year.
- General and administrative expenses totaled $3.3 million for Q3, down from $3.7 million last year.
- Commercial expenses increased significantly to $4.6 million, reflecting heightened operational preparations for the product launch.
- The company's net loss for the third quarter was reported at $11.9 million, compared to $9.4 million for the prior year.
Regulatory Updates and Launch Preparations
Milestone is not only focusing on PSVT but also on the potential of etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR). The company is gearing up to enter a pivotal Phase 3 program in AFib-RVR, taking lessons learned from the successful ReVeRA Phase 2 trial.
Investment Plans and Shareholder Value
Milestone's strategic focus includes leveraging its financial strength from the equity offering and amended royalty purchase agreement to support the development and commercialization of CARDAMYST. The company aims to create substantial shareholder value through its innovative cardiovascular treatment solutions.
Looking Ahead
With expectations of FDA approval for CARDAMYST on the horizon, Milestone Pharmaceuticals is optimistic about the first step towards bringing a new therapeutic option to patients managing symptomatic PSVT. Leadership remains committed to efficiently navigating the regulatory landscape while preparing for market entry. Investors are advised to keep a close watch on upcoming milestones as the company approaches its PDUFA date.
Frequently Asked Questions
What is CARDAMYST?
CARDAMYST is an investigational nasal spray containing etripamil, designed to treat symptomatic PSVT.
When is the PDUFA date for CARDAMYST?
The PDUFA date for CARDAMYST is set for December 13, 2025.
What were Milestone’s financials for Q3 2025?
Milestone reported a net loss of $11.9 million and no revenue in Q3 2025.
What are the company's plans for etripamil in AFib-RVR?
Milestone is preparing to enter a pivotal Phase 3 trial for etripamil in AFib-RVR, leveraging findings from previous studies.
How is Milestone funded for the launch of CARDAMYST?
The company is well-funded following a successful equity offering and an amended royalty purchase agreement, enhancing its capacity for a swift launch upon FDA approval.
